Overexpression of miR‐329‐3p sensitizes osteosarcoma cells to cisplatin through suppression of glucose metabolism by targeting LDHA
Authors:
- 15 October 2020
- journal article
- research article
- Published by Wiley in Cell Biology International
- Vol. 45 (4) , 766-774
Abstract
Osteosarcoma (OS) is one of the most frequent malignant bone tumor types. Traditional treatments of OS involve standard chemotherapy or combination with radiation before and after surgery. Cisplatin is one of the most effective chemotherapeutic drugs used for treating osteosarcoma. However, patients with advanced tumor stages develop cisplatin resistance, leading to a major clinical challenge. In this study, we investigated the roles of miR‐329‐3p in cisplatin sensitivity of osteosarcoma cells. We found miR‐329‐3p was significantly downregulated in osteosarcoma tissues compared with normal bone tissues. Overexpression of miR‐329‐3p suppressed osteosarcoma cell proliferation. Moreover, we observed low‐toxic cisplatin treatments suppressed miR‐329‐3p but higher concentrations of cisplatin‐induced miR‐329‐3p expression. In addition, miR‐329‐3p was significantly downregulated in cisplatin‐resistant Saos‐2 cells which displayed elevated glucose metabolism. Overexpression of miR‐329‐3p significantly impaired glucose metabolism of Saos‐2 cells. Bioinformatics analysis and luciferase assay consistently demonstrated the glycolysis enzyme, lactate dehydrogenase‐A (LDHA) was a direct target of miR‐329‐3p in osteosarcoma cells. Rescue experiments revealed restoration of LDHA in miR‐329‐3p‐overexpressed cisplatin‐resistant cells effectively recovered glucose metabolism, resulting in increased cisplatin resistance. This study demonstrates a miR‐329‐3p‐LDHA‐glucose metabolism‐cisplatin resistance axis in osteosarcoma cells, providing a miRNA‐based therapeutic strategy against chemoresistant osteosarcoma.Keywords
This publication has 26 references indexed in Scilit:
- A molecular view of cisplatin's mode of action: interplay with DNA bases and acquired resistancePhysical Chemistry Chemical Physics, 2015
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Osteosarcoma treatment – Where do we stand? A state of the art reviewCancer Treatment Reviews, 2014
- Molecular mechanisms of chemoresistance in osteosarcoma (Review)Oncology Letters, 2014
- MicroRNA 33 Regulates Glucose MetabolismMolecular and Cellular Biology, 2013
- miRNA Signatures Associate with Pathogenesis and Progression of OsteosarcomaCancer Research, 2012
- Overcoming GlutathioneS-Transferase P1–Related Cisplatin Resistance in OsteosarcomaCancer Research, 2008
- Primary bone osteosarcoma in the pediatric age: State of the artCancer Treatment Reviews, 2006
- Chemotherapy resistance in osteosarcoma: current challenges and future directionsExpert Review of Anticancer Therapy, 2006
- Enhancement of cisplatin activity by lonidamine in human ovarian cancer cellsInternational Journal of Cancer, 1992